Epstein–Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV‐associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation

To evaluate the diagnostic and prognostic utility of monitoring the Epstein–Barr virus (EBV) load in the cerebrospinal fluid (CSF) and peripheral blood for the patients with EBV‐associated central nervous system (CNS) diseases after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), 172 patients undergoing allo‐HSCT were enrolled in the study.

[1]  Can Liu,et al.  Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies , 2012, Journal of Hematology & Oncology.

[2]  A. Bręborowicz,et al.  Pulmonary lymphomatoid granulomatosis in Griscelli syndrome type 2. , 2011, Viral immunology.

[3]  Y. Nojima,et al.  Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder , 2011, International journal of hematology.

[4]  E. Holler,et al.  Isolated cerebral manifestation of Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[5]  J. González-Darder,et al.  Tumoral presentation of primary central nervous system lymphomatoid granulomatosis , 2011, Acta Neurochirurgica.

[6]  J. Schiefer,et al.  Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  K. Rezvani,et al.  Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  M. Mohty,et al.  The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation , 2011, Leukemia.

[9]  N. Ezemba,et al.  Pulmonary Lymphomatoid Granulomatosis: Report of A Case and Review of Literature , 2011, Nigerian medical journal : journal of the Nigeria Medical Association.

[10]  L. Barzon,et al.  A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell Transplantation , 2010, Transplantation.

[11]  M. Gulley,et al.  Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative Disorder , 2010, Clinical Microbiology Reviews.

[12]  H. Heslop.  How I treat EBV lymphoproliferation. , 2009, Blood.

[13]  Zu-jun Jiang,et al.  Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  H. Einsele,et al.  Outcome of treatment of Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[15]  E. Jaffe,et al.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[16]  H. Einsele,et al.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.

[17]  Chung-Wu Lin,et al.  Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute , 2009, Bone Marrow Transplantation.

[18]  Z. Fan,et al.  [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation]. , 2008, Zhonghua yi xue za zhi.

[19]  S. Webber,et al.  Screening for PTLD in lung and heart–lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR , 2008, Pediatric transplantation.

[20]  M. Asaka,et al.  Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  B. Gruhn,et al.  Monitoring of Epstein‐Barr virus load after hematopoietic stem cell transplantation for early intervention in post‐transplant lymphoproliferative disease , 2008, Journal of medical virology.

[22]  H. Haario,et al.  Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  K. Hedman,et al.  Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. , 2007, Haematologica.

[24]  Z. Gu,et al.  Comparison of Various Blood Compartments and Reporting Units for the Detection and Quantification of Epstein-Barr Virus in Peripheral Blood , 2007, Journal of Clinical Microbiology.

[25]  K. Sullivan,et al.  Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Falk,et al.  Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction , 2007, Scandinavian journal of infectious diseases.

[27]  A. Heinz,et al.  Psychiatric symptoms and cognitive dysfunction caused by Epstein–Barr virus-induced encephalitis , 2006, European Psychiatry.

[28]  M. Robin,et al.  Primary Epstein-Barr virus infection with pneumonia transmitted by allogeneic bone marrow after transplantation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Bitan.  Epstein-Barr virus infection after stem cell transplantation: new concepts are needed both for the donor and the recipient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  H. Seuánez,et al.  Diagnostic Pathology BioMed Central Methodology , 2006 .

[31]  Yu-Hong Chen,et al.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.

[32]  A. Bosi,et al.  Epstein–Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation , 2006, Leukemia & lymphoma.

[33]  O. Sharma,et al.  Epstein-Barr-virus-induced interstitial lung disease , 2005, Current opinion in pulmonary medicine.

[34]  D. Rossi,et al.  Post‐transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis , 2005, Hematological oncology.

[35]  H. Heslop,et al.  Post-transplant lymphoproliferative disorders. , 2005, Annual review of medicine.

[36]  R. Krance,et al.  Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.

[37]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[38]  R. Küppers.  B cells under influence: transformation of B cells by Epstein–Barr virus , 2003, Nature Reviews Immunology.

[39]  H. Kanegane,et al.  Epstein‐Barr virus (EBV)‐associated post‐transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation , 2003, American journal of hematology.

[40]  R. Cavallo,et al.  Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients. , 2003, The new microbiologica.

[41]  K. Tyler,et al.  Quantitative CSF PCR in Epstein–Barr virus infections of the central nervous system , 2002, Annals of neurology.

[42]  R. DeBiasi,et al.  Use of PCR for the diagnosis of herpesvirus infections of the central nervous system. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[43]  C. Montpellier,et al.  Human Monocytic Cell Lines Transformed In Vitro by Epstein-Barr Virus Display a Type II Latency and LMP-1-Dependent Proliferation , 2002, Journal of Virology.

[44]  F. Baldanti,et al.  Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. , 2002, Blood.

[45]  K. Roemer,et al.  Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease , 2002, Journal of Clinical Microbiology.

[46]  J. Willem,et al.  Epstein-Barr virus ( EBV ) reactivation is a frequent event after allogeneic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted stem cell transplantation , 2002 .

[47]  A. Fischer,et al.  Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children , 2001, British journal of haematology.

[48]  R. DeBiasi,et al.  Polymerase Chain Reaction as a Diagnostic Adjunct in Herpesvirus Infections of the Nervous System , 2001, Brain pathology.

[49]  H. Jenson.  Acute complications of Epstein-Barr virus infectious mononucleosis , 2000, Current opinion in pediatrics.

[50]  Zhensheng Liu,et al.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.

[51]  F. Baldanti,et al.  High Levels of Epstein-Barr Virus DNA in Blood of Solid-Organ Transplant Recipients and Their Value in Predicting Posttransplant Lymphoproliferative Disorders , 2000, Journal of Clinical Microbiology.

[52]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[53]  M. Dierich,et al.  Epstein-Barr Virus Infection of Human Astrocyte Cell Lines , 1999, Journal of Virology.

[54]  R. Skinner,et al.  Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia , 1999, Bone Marrow Transplantation.

[55]  M. Landgren,et al.  Diagnosis of Epstein‐Barr virus–induced central nervous system infections by DNA amplification from cerebrospinal fluid , 1994, Annals of neurology.